{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:37Z","timestamp":1792782877382,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2022 Wannan Medical College Talent Introduction Special Fund","award":["YR20230122"],"award-info":[{"award-number":["YR20230122"]}],"id":[{"id":"https:\/\/ror.org\/037ejjy86","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Wannan Medical College Horizontal Research Projects","award":["662202404013"],"award-info":[{"award-number":["662202404013"]}],"id":[{"id":"https:\/\/ror.org\/037ejjy86","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Cyclophosphamide (CTX) combined with glucocorticoids and rituximab (RTX) are widely used for idiopathic membranous nephropathy (IMN), but clinical data comparing them in newly diagnosed patients with impaired renal function (eGFR\u2009&lt;\u200960\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) remain scarce. This study aimed to compare their efficacy, safety, and effects on renal function in this specific population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted at the First Affiliated Hospital of Wannan Medical University from November 2019 to July 2024, including 113 newly diagnosed IMN patients (55 in the CTX group, 58 in the RTX group) diagnosed by renal biopsy or positive PLA2R antibodies. All patients were treatment-naive and followed for\u2009\u2265\u20096\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 6\u00a0months, composite remission rates were 69.09% in the CTX group and 62.07% in the RTX group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). At 12\u00a0months, the RTX group showed a numerically higher composite remission rate (83.87% vs. 70.83% in CTX group) without statistical significance (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.186). By 18\u00a0months, both groups reached 73.68% composite remission (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20091.000). In the subgroup with eGFR\u2009&lt;\u200960\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , RTX significantly improved renal function at 6\u00a0months (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008), while CTX showed no significant improvement (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.113); however, no intergroup difference in eGFR was observed (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.793). The CTX group had a higher incidence of non-serious adverse events, including leukopenia and mild infections (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). HypoIgGemia was documented in 5 patients (8.62%) in the RTX group, all mild and asymptomatic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RTX shows comparable efficacy and better safety relative to CTX in this cohort, and may be a preferred option for newly diagnosed untreated IMN, especially in those with early renal impairment. RTX demonstrated comparable efficacy to CTX in newly diagnosed IMN but with superior safety. Notably, RTX showed greater short-term (6-month) renal function improvement in patients with early renal impairment, though long-term effects need further verification in larger-sample prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02895-w","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:41:40Z","timestamp":1780890100000},"page":"1495-1503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab vs. cyclophosphamide in treatment-naive IMN: efficacy and renal protection in early renal impairment"],"prefix":"10.1007","volume":"30","author":[{"given":"Qi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1867-9778","authenticated-orcid":false,"given":"Yanlang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"1","key":"2895_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69. https:\/\/doi.org\/10.1038\/s41572-021-00303-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2895_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/cjn.04321007","volume":"3","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol. 2008;3(3):905\u201319. https:\/\/doi.org\/10.2215\/cjn.04321007.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2895_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/asn.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899\u2013904. https:\/\/doi.org\/10.1681\/asn.2007020166.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2895_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/s0270-9295(03)00049-4","volume":"23","author":"RJ Glassock","year":"2003","unstructured":"Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003;23(4):324\u201332. https:\/\/doi.org\/10.1016\/s0270-9295(03)00049-4.","journal-title":"Semin Nephrol"},{"issue":"4","key":"2895_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753\u201379. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015.","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"2895_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000481635","volume":"47","author":"AS Bomback","year":"2018","unstructured":"Bomback AS, Fervenza FC. Membranous nephropathy: approaches to treatment. Am J Nephrol. 2018;47(Suppl 1):30\u201342. https:\/\/doi.org\/10.1159\/000481635.","journal-title":"Am J Nephrol"},{"issue":"11","key":"2895_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004293.pub4","volume":"11","author":"TC von Groote","year":"2021","unstructured":"von Groote TC, Williams G, Au EH, et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021;11(11):Cd004293. https:\/\/doi.org\/10.1002\/14651858.CD004293.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1(Suppl 1","key":"2895_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/ar3908","volume":"15","author":"MJ Leandro","year":"2013","unstructured":"Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15(Suppl 1(Suppl 1)):S3. https:\/\/doi.org\/10.1186\/ar3908.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2895_CR9","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","volume":"14","author":"JML Casan","year":"2018","unstructured":"Casan JML, Wong J, Northcott MJ, et al. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820\u201341. https:\/\/doi.org\/10.1080\/21645515.2018.1508624.","journal-title":"Hum Vaccin Immunother"},{"key":"2895_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1024068","volume":"13","author":"JM Hartinger","year":"2022","unstructured":"Hartinger JM, Kratky V, Hruskova Z, et al. Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Front Immunol. 2022;13:1024068. https:\/\/doi.org\/10.3389\/fimmu.2022.1024068.","journal-title":"Front Immunol"},{"issue":"2","key":"2895_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2024.2409353","volume":"46","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ma X, Yang X, et al. A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy. Ren Fail. 2024;46(2):2409353. https:\/\/doi.org\/10.1080\/0886022x.2024.2409353.","journal-title":"Ren Fail"},{"key":"2895_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1156470","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Huang J, Dong J, et al. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study. Front Immunol. 2023;14:1156470. https:\/\/doi.org\/10.3389\/fimmu.2023.1156470.","journal-title":"Front Immunol"},{"key":"2895_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111718","volume":"130","author":"P Yan","year":"2024","unstructured":"Yan P, Fang X, Ke B. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: a single-center retrospective cohort study. Int Immunopharmacol. 2024;130:111718. https:\/\/doi.org\/10.1016\/j.intimp.2024.111718.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2895_CR14","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"11","key":"2895_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: improving Global Outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825\u201330. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00007.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2895_CR16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","volume":"6","author":"P Gauckler","year":"2021","unstructured":"Gauckler P, Shin JI, Alberici F, et al. Rituximab in membranous nephropathy. Kidney Int Rep. 2021;6(4):881\u201393. https:\/\/doi.org\/10.1016\/j.ekir.2020.12.035.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"2895_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","volume":"5","author":"N Hanset","year":"2020","unstructured":"Hanset N, Esteve E, Plaisier E, et al. Rituximab in patients with Phospholipase A2 Receptor-associated membranous nephropathy and severe CKD. Kidney Int Rep. 2020;5(3):331\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2019.12.006.","journal-title":"Kidney Int Rep"},{"issue":"5 Pt 2","key":"2895_CR18","first-page":"146s","volume":"17","author":"RA Fleming","year":"1997","unstructured":"Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997;17(5 Pt 2):146s\u201354s.","journal-title":"Pharmacotherapy"},{"issue":"4s","key":"2895_CR19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"KDIGO","year":"2021","unstructured":"KDIGO. 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s):S1-s276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","journal-title":"Kidney Int"},{"issue":"9","key":"2895_CR20","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/asn.2016091022","volume":"28","author":"J van den Brand","year":"2017","unstructured":"van den Brand J, Ruggenenti P, Chianca A, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol. 2017;28(9):2729\u201337. https:\/\/doi.org\/10.1681\/asn.2016091022.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2895_CR21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1681\/asn.V93444","volume":"9","author":"C Ponticelli","year":"1998","unstructured":"Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9(3):444\u201350. https:\/\/doi.org\/10.1681\/asn.V93444.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2895_CR22","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/asn.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor antibody titer predicts post-Rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545\u201358. https:\/\/doi.org\/10.1681\/asn.2014070640.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2895_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/asn.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO Randomized Trial. J Am Soc Nephrol. 2021;32(4):972\u201382. https:\/\/doi.org\/10.1681\/asn.2020071091.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02895-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02895-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02895-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:51:09Z","timestamp":1789613469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02895-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2895"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02895-w","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No potential conflict of interest was reported by the authors.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}